Abstract:The EGFR family play a significant role in cell signal transduction and their overexpression is implicated in the pathogenesis of numerous human solid cancers. Inhibition of the EGFR-mediated signaling pathways by EGFR inhibitors is a widely used strategy for the treatment of cancers. In most cases, the EGFR inhibitors used in clinic were only effective when the cancer cells harbored specific activating EGFR mutations which appeared to preserve the ligand-dependency of receptor activation but altered the pattern of downstream signaling pathways. Moreover, cancer is a kind of multifactorial disease, and therefore manipulating a single target may result in treatment failure. Although drug combinations for the treatment of cancers proved to be successful, the use of two or more drugs concurrently still was a challenge in clinical therapy owing to various dose-limiting toxicities and drug-drug interactions caused by pharmacokinetic profiles changed. Therefore, a single drug targeting two or multiple targets could serve as an effective strategy for the treatment of cancers. In recent, drugs with diverse pharmacological effects have been shown to be more advantageous than combination therapies due to their lower incidences of side effects and more resilient therapies. Accordingly, dual target-single-agent strategy has become a popular field for cancer treatment, and researchers became more and more interest in the development of novel dual-target drugs in recent years. In this review, we briefly introduce the EGFR family proteins and synergisms between EGFR and other anticancer targets, and summarizes the development of potential dual target inhibitors based on wild-type and/or mutant EGFR for the treatment of solid cancers in the past five years. Additionally, the rational design and SARs of these dual target agents are also presented in detailed, which will lay a significant foundation for the further development of novel EGFR-based dual inhibitors with excellent druggability.

Recent researches for dual Aurora target inhibitors in antitumor field

Clinical development of dual tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor and platelet- derived growth factor receptor

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

The significant others of aurora kinase a in cancer: combination is the key

Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies

Emerging roles of Aurora-A kinase in cancer therapy resistance

Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy

The Role of Aurora-A in Human Cancers and Future Therapeutics.

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Selective Aurora A-TPX2 interaction inhibitors have efficacy as targeted anti-mitotic agents

Combination of AURKA Inhibitor and HSP90 Inhibitor to Treat Breast Cancer with AURKA Overexpression and TP53 Mutations

Recent development of BTK-based dual inhibitors in the treatment of cancers

Breaking the 'undruggable' barrier: Revealing molecular mechanisms in Aurora Kinase A/Myc protein interplay targeting cancers

Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents

HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode